Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Xcovery Holdings, Inc.

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Xcovery Holdings, Inc.
Via Business Wire
U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib
From Xcovery Holdings, Inc.
Via Business Wire
Xcovery SHP2 Inhibitor IND Approved by US FDA
From Xcovery Holdings, Inc.
Via Business Wire
Ensartinib Secured Its First Approval for 1st Line Treatment in ALK+ NSCLC
From Xcovery Holdings, Inc.
Via Business Wire
Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals
From Xcovery Holdings, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.